Co-pay Cards & Patient Savings Offers
Pfizer Oncology Together
Phase III Study Primary Endpoints
Success in ISGA: Clear or almost clear
Phase III Study Secondary Endpoints
ISGA clear or almost clear
Time to ISGA success
Phase III Study: Other Endpoints
Quality of life assessments
Infant Study: Exploratory efficacy Endpoints
ISGA clear or almost clear
%BSA, EASI & POEM
Phase III Study Adverse Reactions*
Pivotal trial & 48-week extension study
Open-Label Safety Extension Study*
Open-Label Safety Extension Study Rescue Therapy Endpoint
Infant Safety Study**
Study design and Demographics
Savings & Support
Cost and Coverage
*Eligible patients pay as little as $10
*Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,880. This card will be accepted only at participating pharmacies. This card is not health insurance.
** This is an optional area where footnotes can live.
* Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,800. This card will be accepted only at participating pharmacies. This card is not health insurance.
Favorable access on many plans nationwide and is available at the lowest branded copay for many commercial and Medicare patients.
Register or sign in to check availability and request samples.
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.
Warnings and Precautions
Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.
The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.
EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.
Please see full Prescribing Information.
OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.
If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.
Would you like to sign in now?